Janssen Announces BCMA CAR-T Therapy JNJ-4528 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Relapsed or Refractory Multiple Myeloma

Newest designation for JNJ-4528 is supported by Phase 1b/2 CARTITUDE-1 study in adults with relapsed or refractory multiple myelomaInitial results from CARTITUDE-1 study to premiere at the American Society of Hematology Annual Meeting
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news